Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 172

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Open access
Narula, Neeraj, Peerani, Farhad, Meserve, Joseph, Kochhar, Gursimran, Chaudrey, Khadija, Hartke, Justin, Chilukuri, Prianka, Koliani-Pace, Jenna, Winters, Adam, Katta, Leah, Shmidt, Eugenia, Hirten, Robert, Faleck, David, Parikh, Malav P., Whitehead, Diana, Boland, Brigid S., Singh, Siddharth, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Barocas, Morris, Luo, Michelle, Lasch, Karen, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Shen, Bo, Kane, Sunanda, Loftus, Edward V., Siegel, Corey A., Sands, Bruce E., Colombel, Jean-Frederic, Sandborn, William J., Dulai, Parambir S. · 2018 · American Journal of Gastroenterology

Abstract

OBJECTIVES: We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, and to identify predictors of response to treatment. METHODS: Retrospective review (May 2014-December 2016) of VICTORY Consortium data. Adults with follow-up after starting VDZ for clinically active UC were included. Primary effectiveness outcomes were cumulative rates of clinical remission (resolution of all UC-related symptoms) and endoscopic remission (Mayo endoscopic sub-score 0). Key secondary effectiveness outcomes included cumulative rates of corticosteroid-free remission and deep remission (clinical remission and endoscopic remission). Cox proportional hazard analyses were used to identify independent predictors of treatment effectiveness. Non-response imputation (NRI) sensitivity analyses were performed for effectiveness outcomes. Key safety outcomes were rates of serious infection, serious adverse events, and colectomy. RESULTS: We included 321 UC patients (71% prior TNFα antagonist exposure, median follow-up 10 months). The 12-month cumulative rates of clinical remission and endoscopic remission were 51% and 41%, respectively. Corresponding rates for corticosteroid-free remission and deep remission were 37% and 30%, respectively. Using NRI, 12-month rates were 20% (n = 64/321) for clinical remission, 17% (n = 35/203) for endoscopic remission, 15% (n = 30/195) for corticosteroid-free remission, and 14% (n = 28/203) for deep remission. A majority of the patients without adequate follow-up at 12 months who were deemed non-responders using NRI had already achieved clinical remission (n = 70) or a significant clinical response (n = 36) prior to 12 months. VDZ discontinuation prior to 12 months was observed in 91 patients, for lack of response (n = 56), need for surgery (n = 29), or adverse event (n = 6). On multivariable analyses, prior exposure to a TNFα antagonist was associated with a reduced probability of achieving clinical remission (HR 0.53, 95% CI 0.38-0.75) and endoscopic remission (HR 0.51, 95% CI 0.29-0.88). Serious adverse events and serious infections were reported in 6% and 4% of patients, respectively. Overall cumulative rates of colectomy over 12 months were 13%, with lower rates observed in patients naive to TNFα antagonist therapy (2%) than those who had been exposed to TNFα antagonists (19%). CONCLUSION: In this large real-world cohort we observed that VDZ was well tolerated and effective in achieving key clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41395-018-0162-0

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 172

Metadata

Authors
Narula, N., Peerani, F., Meserve, J., Kochhar, G., Chaudrey, K., Hartke, J., Chilukuri, P., Koliani-Pace, J., Winters, A., Katta, L., Shmidt, E., Hirten, R., Faleck, D., Parikh, M. P., Whitehead, D., Boland, B. S., Singh, S., Sagi, S. V., Fischer, M., Chang, S., Barocas, M., Luo, M., Lasch, K., Bohm, M., Lukin, D., Sultan, K., Swaminath, A., Hudesman, D., Gupta, N., Shen, B., Kane, S., Loftus, E. V., Siegel, C. A., Sands, B. E., Colombel, J.-F., Sandborn, W. J., & Dulai, P. S.
Venue
American Journal of Gastroenterology
Published
2018-09
Volume
113
Issue
9
Pages
1345
ISSN
0002-9270 (ISSN-L)
OpenAlex
W2809894743
Cited by
172
References
1
FWCI
12.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. https://app.cochat.ai/papers/10.1038/s41395-018-0162-0
The paper
Narula, N., Peerani, F., Meserve, J., Kochhar, G., Chaudrey, K., Hartke, J., Chilukuri, P., Koliani-Pace, J., Winters, A., Katta, L., Shmidt, E., Hirten, R., Faleck, D., Parikh, M. P., Whitehead, D., Boland, B. S., Singh, S., Sagi, S. V., Fischer, M., . . . Dulai, P. S. (2018). Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology. https://doi.org/10.1038/s41395-018-0162-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.